Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Drug Reaction with Eosinophilia and Systemic Symptoms" (DRESS): Long-term Outcomes Based on Severity - A Cohort Study.

Acta dermato-venereologica·2026
Same author

Descriptive Analysis of DRESS Reports from EudraVigilance and DRESS Cases from the RegiSCAR-project.

Dermatology (Basel, Switzerland)·2026
Same author

La prise en charge de la dilatation des voies urinaires en période anténatale : un point de pratique clinique pour les prestataires de soins néonatals.

Paediatrics & child health·2026
Same author

Thyrostatic Drugs and Severe Skin Reactions: A Registry Evaluation Over 20 Years.

Deutsches Arzteblatt international·2026
Same author

Toward actionable interventions in human aging (12th ARDD meeting, 2025).

Aging·2026
Same author

Development and Evaluation of a Baicalin-Loaded Phytosomal Transdermal Patch for Type 2 Diabetes Mellitus.

Current drug metabolism·2026

Related Experiment Video

Updated: May 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Telaprevir-related dermatitis.

Jean-Claude Roujeau1, Maja Mockenhaupt, Steven R Tahan

  • 1Department of Dermaology, Université Paris-Est, Créteil, France.

JAMA Dermatology
|April 6, 2013
PubMed
Summary
This summary is machine-generated.

Telaprevir treatment for hepatitis C frequently causes eczematous dermatitis. Vigilance is crucial for potential severe reactions like Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: May 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

  • Hepatology
  • Dermatology
  • Clinical Pharmacology

Background:

  • Hepatitis C virus (HCV) infection is a major global health concern.
  • Telaprevir, a protease inhibitor, has been used in combination therapy for HCV.
  • Skin reactions are a known adverse event associated with antiviral therapies.

Purpose of the Study:

  • To determine the incidence, type, and severity of skin reactions associated with telaprevir.
  • To characterize the clinical presentation of telaprevir-induced dermatitis.
  • To assess the risk of severe cutaneous adverse events (SCARs) such as Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Main Methods:

  • A review of skin eruptions reported as moderate or severe in telaprevir clinical trials (Phase 1-3).
  • Assessment by three blinded dermatologists using clinical summaries, photographs, and biopsy results.
  • Analysis of data from telaprevir combination therapy trials for hepatitis C.

Main Results:

  • Skin eruptions occurred in 56% of telaprevir-treated patients versus 34% in the control group (pegylated interferon and ribavirin alone).
  • Severe skin reactions were reported in 3.7% of telaprevir patients compared to 0.4% in the control group.
  • The most common reaction was pruritic eczematous dermatitis (over 90% of cases), distinct from typical drug eruptions. Suspected cases of SJS and DRESS were identified.

Conclusions:

  • A majority of patients treated with telaprevir develop a characteristic eczematous dermatitis.
  • The timing and appearance of this dermatitis differ from common drug reactions.
  • There is an increased risk for severe reactions like DRESS and SJS, necessitating careful monitoring of telaprevir-treated patients.